|
Video: What is a Stock Split?
|
|
Mereo Biopharma Group is a biopharmaceutical company focused on the development of therapeutics for rare diseases. Co.'s oncology and rare disease product candidates include: Setrusumab (BPS-804), which is an antibody designed to inhibit sclerostin, a protein that inhibits the activity of bone-forming cells; Alvelestat (MPH-966), which is an oral small molecule Co. is developing for the treatment of severe alpha-1 antitrypsin deficiency lung disease and bronchiolitis obliterans syndrome; and Etigilimab (MPH-313), which is an antibody against T-cell immunoreceptor with Ig and ITIM domains. According to our Mereo BioPharma Group PLC stock split history records, Mereo BioPharma Group PLC has had 0 splits. | |
|
Mereo BioPharma Group PLC (MREO) has 0 splits in our Mereo BioPharma Group PLC stock split history database.
Looking at the Mereo BioPharma Group PLC stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Mereo BioPharma Group PLC shares, starting with a $10,000 purchase of MREO, presented on a split-history-adjusted basis factoring in the complete Mereo BioPharma Group PLC stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/25/2019 |
|
End date: |
04/17/2024 |
|
Start price/share: |
$5.92 |
|
End price/share: |
$2.58 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-56.42% |
|
Average Annual Total Return: |
-15.35% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$4,358.37 |
|
Years: |
4.98 |
|
|
|
|
|